Gliclazide modified release: A critical review of pharmacodynamic, metabolic, and vasoprotective effects

Metabolism: Clinical and Experimental

Volumn 52, Issue 8 SUPPL. 1, 2003, Pages 29-34

  Schernthaner, Guntram ^a  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM); GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN; ORAL ANTIDIABETIC AGENT; POTASSIUM CHANNEL; SULFONYLUREA;

ARTHRALGIA; ARTHRITIS; BRONCHITIS; CLINICAL TRIAL; DIABETIC ANGIOPATHY; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG RELEASE; DRUG SAFETY; DRUG SELECTIVITY; GLUCOSE BLOOD LEVEL; HEART PROTECTION; HUMAN; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; LONG TERM CARE; LOW BACK PAIN; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

EID: 0042887648     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(03)00215-4     Document Type: Article

References (47)

1. UKPDS Group: Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
2. European Diabetes Policy Group: A desktop guide to type 2 diabetes mellitus. Diabet Med 16:716-730, 1999
3. Winter WE: Type 2 diabetes mellitus: The challenge of a metabolic epidemic. J Clin Ligand Assay 21:293-308, 1998
4. Gaede P, Vedel P, Larsen, N, et al: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
5. Harrower A: Gliclazide modified release: From once daily administration to 24-hour blood glucose control. Metabolism 49:7-11, 2000 (suppl 2)
6. Francillard M, Frey N, Paraire M, et al: Pharmacokinetics of Diamicron Modified Release (MR) in 1007 type 2 diabetic patients. J Nutr Health Aging 5:31, 2001 (abstr F14)
7. Reaven GM, Hollenbeck C, Jeng C-Y, et al: Measurement of plasma glucose, free fatty acid, lactate and insulin for 24 hr in patients with NIDDM. Diabetes 38:1020-1024, 1988
8. Delrat P, Paraire M, Jochemsen R: Complete bioavailability and lack of food effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers. Biopharm Drug Dispos 23:151-157, 2002
9. Guillausseau PJ, Greb WH: 24-Hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once daily. Diabetes Metab 27:133-137, 2001
10. Paes AHD, Bakker A, Soe-Agnié CJ: Impact of dosage frequency on patient compliance. Diabetes Care 20:1512-1517, 1997
11. Guillausseau P-J: Influence of compliance with treatment on metabolic control in type 2 diabetes. A survey in general practice. Diabetes Metab 29:79-81, 2003
12. Drouin P for the Diamicron MR Study Group: Two year efficacy and safety of Diamicron MR in inadequately controlled patients with type 2 diabetes. J Nutr Health Aging 5:31, 2001 (abstr 14)
13. Drouin P for the Diamicron MR Study Group: Diamicron MR once daily is effective and well-tolerated in type 2 diabetes: A double-blind randomized, multinational study. J Diabetes Complications 14:185-191, 2000
14. De Fronzo RA, Tobin JD, Andres R: Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 6:214-233, 1979
15. Fujita Y, Herron AL, Seltzer HS: Confirmation of impaired early insulin responses to glucose in non-obese diabetic subjects. J Clin Invest 51:1624-1631, 1972
16. De Fronzo RA, Bonadonna RC, Ferrannini A: Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15:318-368, 1992
17. Della Casa L, Del Rio G, Glaser B, et al: Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: Role of initial continuous subcutaneous insulin infusion induced normoglycemia. Am J Med 90:37S-45S, 1990 (suppl)
18. Hosker JP, Rudenski AS, Burnett MA, et al: Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type 2 diabetes and the effect of gliclazide therapy. Metabolism 38:767-772, 1989
19. Ligtenberg JJM, Reitsma WD, Van Haeften TW: Gliclazide mainly affects insulin secretion in second phase of type 2 diabetes mellitus. Horm Metab Res 33:361-364, 2001
20. UKPDS Group: UK prospective diabetes study 24: Relative efficacy of sulfonylurea, insulin and metformin therapy in newly diagnosed non-insulin dependent diabetes with primary diet failure followed for six years. Ann Intern Med 128:165-175, 1998
21. Cerasi E: Does gliclazide stimulate first-phase, second phase, or both phases of insulin release? Horm Metab Res 34:107-108, 2002
22. Palmer KJ, Brogden RN: Gliclazide, an update on its pharmacological properties and therapeutic efficacy in non-insulin dependent diabetes mellitus. Drugs 46:92-125, 1993
23. Pulido N, Suarez, A, Casanova B, et al: Gliclazide treatment of streptozotocin diabetic rats restores Glut4 protein content and basal glucose uptake in skeletal muscle. Metabolism 46:10-13, 1997
24. Riccio A, Lisato G, Vigilli De Kreutzenberg S, et al: Gliclazide potentiates suppression of hepatic glucose production in non-insulin-dependent diabetic patients. Metabolism 45:1196-1202, 1996
25. Kimoto K, Suzuki K, Kizaki T, et al: Gliclazide protects pancreatic β-cells from damage by hydrogen peroxide. Biochem Biophys Res Commun 303:112-119, 2003
26. + channels and insulin secretion: Their role in health and disease. Diabetologia 42:903-919, 1999
27. Gribble FM, Ashcroft FM: Differential sensitivity of β-cell and extrapancreatic K ATP channels to gliclazide. Diabetologia 42:845-848, 1999
28. Gribble FM, Tucker SJ, Seino S, et al: Tissue specificity of sulfonylureas: Studies on cloned cardiac and β cell KATP channels. Diabetes 47:1412-1418, 1998
29. Song DK, Ashcroft FM: Glimepiride block of cloned β-cell, cardiac and smooth muscle KATP channels. Br J Pharmacol 133:193-199, 2001
30. Reimann F, Ashcroft FM, Gribble FM: Structural basis for the interference between nicorandil and sulfonylurea action. Diabetes 50:2253-2259, 2001
31. Ravel D, Levens N, Félétou M, et al: Differential effects of sulfonylureas on the vasodilatory response evoked by KATP channel openers. Fundam Clin Pharmacol 17:61-69, 2003
32. Wascher TC, Boes U: Different effects of glibenclamide and gliclazide on forearm vascular reserve in type 2 diabetic patients. Diabetologia 45:A275, 2002 (suppl 2, abstr)
33. Tooke JE: Endothelium: The main actor or choreographer in the remodeling of the microvasculature in diabetes? Diabetologia 39:745-746, 1996
34. Oughton J, Barnes AJ, Kohner EM: Diabetes mellitus: Its effect on the flow properties of blood. Horm Metab Res 11:112-120, 1981 (suppl)
35. Thompson SG, Kienast J, Pyhe SD, et al: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 332:635-641, 1995
36. Scott NA, Jennings PE, Brown J, et al: Gliclazide: A free radical scavanger. Eur J Pharmacol 208:175-177, 1991
37. O'Brien RC, Luo M, Balazs N, et al: In-vitro and in-vivo antioxidant properties of gliclazide. J Diabetes Complications 14:201-206, 2000
38. Desfaits AC, Serri O, Renier G: Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment. Diabetes Care 21:487-493, 1998
39. Omi H, Okayama N, Shimizu M, et al: Participation of high glucose concentrations in neutrophil adhesion and surface expression of adhesion molecules on cultured human endothelial cells: Effect of antidiabetic medicines. J Diabetes Complications 16:321-326, 2002
40. Itoh M, Omi H, Okouchi M, et al: The mechanisms of inhibitory actions of gliclazide on neutrophils-endothelial cells adhesion and surface expression of endothelial adhesion molecules mediated by a high glucose concentration. J Diabetes Complications 17:22-26, 2003
41. Fava D, Cassone-Faldetta M, Laurenti O, et al: Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in type 2 diabetes. Diabet Med 19:752-757, 2002
42. Jennings P, Scott NA, Saniabadi AR, et al: Effects of gliclazide on platelet reactivity and free radicals in type 2 diabetic patients: Clinical assessment. Metabolism 5:36-39, 1992
43. Gram J, Jespersen J, Kold A: Effects of an oral antidiabetic drug on the fibrinolytic system of blood in insulin-treated diabetic patients. Metabolism 37:939-943, 1988
44. Siluk D. Kaliszan R, Haber P, et al: Antiaggregatory activity of hypoglycaemic sulphonylureas. Diabetologia 45:1034-1037, 2002
45. Kinoshita N, Kakehashi A, Inoda S, et al: Effective and selective prevention of retinal leukostasis in streptozotocin-induced diabetic rats using gliclazide. Diabetologia 45:735-739, 2002
46. Akanuma Y, Kosaka K, Kanazawa Y, et al: Diabetic retinopathy in non-insulin dependent diabetes mellitus patients: The role of gliclazide. Am J Med 90:74-76, 1991
47. Study rationale and design of ADVANCE: Action in Diabetes and Vascular disease - PreterAx and DiamicroN MR Controlled Evaluation. Diabetologia 44:1118-1120, 2001